BDSX Earnings Date: Nov 5, 2026 (Estimated) — Biodesix, Inc.
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is BDSX's next earnings date?
Biodesix, Inc. (BDSX) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.75 on revenue of $27.5M.
How did BDSX do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Biodesix, Inc. posted EPS of -$0.71 versus the -$0.90 estimate, a beat of 20.2%. Revenue was $26.9M against a $26.0M estimate. The stock's 1-day post-earnings move was -3.0%.
How much does BDSX stock move after earnings?
BDSX beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 12.7% (up or down) in the day after earnings.
About Biodesix, Inc.
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.90 | -0.71 | +20.22% | $26.9M | ✅ Beat | -2.99% | +6.32% | +16.22% |
| 2026-05-04 | Q1 2026 | -1.13 | -0.81 | +28.32% | $25.6M | ✅ Beat | +32.56% | +42.95% | +42.86% |
| 2026-02-26 | Q4 2025 | -0.94 | -0.49 | +47.87% | $28.8M | ✅ Beat | +7.81% | +11.53% | -0.07% |
| 2025-11-03 | Q3 2025 | -1.54 | -1.16 | +24.68% | $21.8M | ✅ Beat | +19.87% | +18.93% | +28.39% |
| 2025-08-07 | Q2 2025 | -0.07 | -0.08 | -14.29% | $20.0M | ❌ Miss | -10.40% | -11.19% | -3.31% |
| 2025-03-03 | Q4 2024 | -0.07 | -0.06 | +14.29% | $20.4M | ✅ Beat | +0.98% | +13.11% | -15.01% |
| 2024-11-01 | Q3 2024 | -0.07 | -0.07 | +0.00% | $18.2M | ➖ Inline | -23.53% | -21.76% | -20.00% |
| 2024-08-07 | Q2 2024 | -0.09 | -0.08 | +11.11% | $17.9M | ✅ Beat | +3.14% | +8.18% | +16.35% |
Showing last 8 quarters.